Modulation of Type 1 Diabetes Risk by the Intestinal Microbiome

Current Diabetes Reports

Volumn 17, Issue 11, 2017, Pages

  Knip, Mikael ^a,b,c,d   Honkanen, Jarno ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^c FOLKHÄLSAN RESEARCH CENTER   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Diet; Microbiome; Microbiota; Prebiotics; Probiotics; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; HLA ANTIGEN; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; VSL3;

AUTOIMMUNE DISEASE; BACTERIAL OVERGROWTH; BACTEROIDETES; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; CHRONIC INFLAMMATION; CLOSTRIDIUM DIFFICILE INFECTION; DNA METHYLATION; DYSBIOSIS; ESCHERICHIA COLI; FECAL MICROBIOTA TRANSPLANTATION; FIRMICUTES; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; METAGENOMICS; MICROBIAL COLONIZATION; MICROBIAL DIVERSITY; NONHUMAN; PHAGE THERAPY; POPULATION ABUNDANCE; REGULATORY T LYMPHOCYTE; REVIEW; SEROCONVERSION; ANIMAL; IMMUNOLOGY; MICROBIOLOGY; RISK FACTOR; RISK REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 1; GASTROINTESTINAL MICROBIOME; HUMANS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 85029831513     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-017-0933-9     Document Type: Review

References (61)

1. Knip M, Korhonen S, Kulmala P, et al. Prediction of type 1 diabetes in the general population. Diabetes Care. 2010;(33, 6):1206–12.
2. Ilonen J, Hammais A, Laine A-P, et al. Patterns of β-cell autoantibody appearance and genetic associations during the first years of life. Diabetes. 2013;62(10):3636–40.
3. Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58(5):980–7.
4. Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(7):a007690.
5. Knip M. Pathogenesis of type 1 diabetes: implications for incidence trends. Horm. Res. 2011;76(Suppl. 1):57–64.
6. Harjutsalo V, Sund R, Knip M, Groop PH. Incidence of type 1 diabetes in Finland. JAMA. 2013;310(4):427–8.
7. Bach JF, Chatenoud L. The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes. Cold Spring Harb Perspect Med. 2012;2(2):a007799.
8. Okada H, Kuhn C, Feillet H, Bach JF. The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update. Clin Exp Immunol. 2010;160(1):1–9.
9. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nature Rev Endocrinol. 2016;12(3):154–67.
10. von Hertzen L, Beutler B, Bienenstock J, et al. Helsinki alert of biodiversity and health. Ann Med. 2015;47(3):218–25.
11. Quercia S, Candela M, Giuliani C, et al. From lifetime to evolution: timescales of human gut microbiota adaptation. Front Microbiol. 2014;5:587.
12. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–73.
13. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.
14. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7485):220–30.
15. Renz H, Brandtzaeg P, Hornef M. The impact of perinatal immune development on mucosal homeostasis and chronic inflammation. Nat Rev Immunol. 2012;12(1):9–23.
16. Sommer F, Bäckhed F. The gut microbiota—masters of host development and physiology. Nat Rev Microbiol. 2013;11(4):227–38.
17. Garn H, Neves JF, Blumberg RS, Renz H. Effect of barrier microbes on organ based inflammation. J Allergy Clin Immunol. 2013;131(6):1465–78.
18. West CE, Jenmalm MC, Prescott SL. The gut microbiota and its role in the development of allergic disease: a wider perspective. Clin Exp Allergy. 2015;45(1):43–53.
19. Giongo A, Mukherjee N, Gano KA, et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011;5(1):82–91.
20. Kupila A, Muona P, Ronkainen M, et al. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes. 2002;51:646–51.
21. Brown CT, Davis-Richardson AG, Giongo A, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011;6(10):e25792.
22. Knip M, Virtanen SM, Seppä K, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010;363(20):1900–8.
23. Vaarala O, Ilonen J, Ruohtula T, et al. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med. 2012;166(7):608–14.
24. de Goffau MC, Luopajärvi K, Knip M, et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes. 2013;62(4):1238–44.
25. Hummel S, Pflüger M, Hummel M, et al. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34(6):1301–5.
26. Endesfelder D, Zu Castell W, Ardissone A, et al. Compromised gut microbiota networks in children with anti-islet cell autoimmunity. Diabetes 2014;63(6)2006–2014.
27. Davis-Richardson A, Ardissone A, Dias R, et al. Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. Front Microbiol. 2014;5:678.
28. Leonard MT, Davis-Richardson AG, Ardissone AN, et al. The methylome of the gut microbiome: a disparate Dam methylation patterns in intestinal Bacteroides dorei. Front Microbiol. 2014;5:361.
29. Kallionpää H, Laajala E, Öling V, et al. The standard of hygiene and immune adaptation in newborn infants. Clin Immunol. 2014;155(1):136–47.
30. •• Kostic AD, Gevers D, Siljander H, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host & Microbe. 2015;17(2):260–73. This observational study found that progression to type 1 diabetes was associated with a decreased microbial diversity and spikes in inflammation-favoring organisms, but these changes emerged after the appearance of β cell autoimmunity.
31. Alkanani AK, Hara N, Gottlieb PA, et al. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes. 2015;64(10):3510–20.
32. Hansen CH, Krych L, Nielsen DS, et al. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia. 2012;55(8):2285–94.
33. Murri M, Leiva I, Gomez-Zumaquero JM, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med. 2013;11:46.
34. Mejía-León ME, Petrosino JF, Ajami NJ, Domínguez-Bello MG, de la Barca AM. Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep. 2014;4:3814.
35. de Goffau MC, Fuentes S, van den Bogert B, et al. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia. 2014;57(8):1569–77.
36. •• Vatanen T, Kostic AD, d’Hennezel E, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165(4):842–53. This observational study provides information on the immune education in Russian and Finnish infants. In Finnish infants, the lipopolysaccharide (LPS) exposure arose primarily from Bacteroides, whereas Eschericia coli was the main source for LPS in Russian infants. The latter LPS stimulated the immune system strongly in contrast to the Bacteroides- derived LPS, which even inhibited the E. coli LPS.
37. Kondrashova A, Reunanen A, Romanov A, et al. A sixfold gradient in the incidence of type 1 diabetes at the eastern border of Finland. Ann Med. 2005;37(1):67–72.
38. Kondrashova A, Seiskari T, Ilonen J, Knip M, Hyöty H. The “hygiene hypothesis” and the sharp gradient in the incidence of autoimmune and allergic diseases between Russian Karelia and Finland. APMIS. 2013;121(6):478–93.
39. Lodinová-Zádniková R, Sonnenborn U. Effect of preventive administration of a non-pathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate. 1997;71(4):224–32.
40. Sturm A, Rilling K, Baumgart DC, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun. 2005;73(3):1452–65.
41. • Dominguez-Bello MG, De Jesus-Laboy KM, Shen N, et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med. 2016;22(3):250–3. This pilot intervention study showed that vaginal microbial transfer to infants born through caesarean section partly restored the oral, skin, and anal microbiota to be similar to that present in vaginally born infants.
42. Yassour M, Vatanen T, Siljander H, et al. Natural history of the infant gut microbiome and impact of antibiotic treatments on bacterial strain diversity and stability. Sci Transl Med. 2016;8(343):343RA81.
43. Cardwell CR, Stene LC, Joner G, et al. Caesarean section is associated with an increased risk of childhood onset type 1 diabetes: a meta-analysis of observational studies. Diabetologia. 2008;51(5):726–35.
44. Hill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific Association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14.
45. Calcinaro F, Dionisi S, Marinaro M, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia. 2005;48(8):1565–75.
46. Uusitalo U, Liu X, Yang J, Aronsson CA, et al. Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr. 2016;170(1):20–8.
47. Smilowitz JT, Moya J, Breck MA, et al. Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial. BMC Pediatr. 2017;17(1):133.
48. Mimee M, Citorik RJ, Lu TK. Microbiome therapeutics—advances and challenges. Adv Drug Deliv Rev. 2016;105(Pt A):44–54. This review discusses strategies to manipulate the microbiota and future challenges in the development of microbiome therapeutics.
49. Panigrahi P. Probiotics and prebiotics in neonatal necrotizing enterocolitis: new opportunities for translational research. Pathophysiology. 2014;21(1):35–46.
50. Coppa GV, Zampini L, Galeazzi T, Gabrielli O. Prebiotics in human milk: a review. Dig Liver Dis. 2006;38(Suppl. 2):S291–4.
51. Marcobal A, Barboza M, Froehlich JW, et al. Consumption of human milk oligosaccharides by gut-related microbes. J Agric Food Chem. 2010;58(95):334–40.
52. Matsuki T, Yahagi K, Mori H, et al. A key genetic factor for fucosyllactose utilization affects infant gut microbiota development. Nat Commun. 2016;7:11939.
53. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(7):1079–87.
54. • Cohen NA, Maharshak N. Novel indications for fecal microbial transplantation: update and review of the literature. Dig Dis Sci. 2017;62(5):1131–45. This review focuses on new indications for fecal microbiota transplantation.
55. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology. 2014;146(6):1573–82.
56. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. Highthroughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013;4(2):125–35.
57. •• Brüssow H. Biome engineering – 2020. Microb Biotechnol. 2016;9(5):553–63. This review discusses the current status of research on gut microbiome interventions and what might be expected until 2020 in this field.
58. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and “western-lifestyle” inflammatory diseases. Immunity. 2014;40(6):833–42.
59. •• Marino E, Richards JL, McLeod KH, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat Immunol. 2017;18(5):552–62. This experimental intervention showed that butyrate- and acetate-yielding diets reduced the incidence of autoimmune diabetes in NOD mice.
60. Le Leu RK, Winter JM, Christophersen CT, et al. Butyrylated starch intake can prevent red meat-induced O6-methyl-2-deoxyguanosine adducts in human rectal tissue: a randomised clinical trial. Br J Nutr. 2015;114(2):220–30.
61. Thaiss CA, Elinav E. The remedy within: will the microbiome fulfill its therapeutic promise? J Mol Med. 2017. https://doi.org/10.1007/s00109-017-1563-z.